About Veracyte
Veracyte is a global genomic diagnostics company that develops and commercializes molecular tests to guide cancer care decisions. The company's high-performing molecular tests empower clinicians and their patients with important information that has helped guide care decisions for over 900,000 people across multiple cancer types. Veracyte's tests assess the unique biology of each patient's tumor to help clinicians answer key questions and make confident decisions for thyroid, prostate, breast, bladder, and lung cancer. The company's portfolio includes the Afirma Genomic Sequencing Classifier for thyroid nodules, Decipher tests for prostate and bladder cancer, Prosigna Breast Risk of Recurrence Test, and TrueMRD Monitoring Test for muscle-invasive bladder cancer. Veracyte's proprietary Diagnostics Platform performs whole-transcriptome profiling on every test sample, creating an ever-expanding database that powers new insights, generates robust clinical evidence, and enables new applications across the cancer care continuum. This integrated approach combines comprehensive genomic profiling, AI-powered analysis, rigorous clinical studies, and expanding test applications to deliver personalized and effective patient care. The platform has generated over 600 peer-reviewed publications and is supported by more than 35 Phase 2 and 3 clinical trials. Veracyte's tests are widely recommended in clinical guidelines, with Decipher Prostate being the only gene expression test included in the NCCN Clinical Practice Guidelines for prostate cancer.
Clinical Focus
Medical conditions and clinical areas addressed by Veracyte.
Who It Serves
Milestones & Awards
Recent Milestones
Commercial launch of Prosigna Breast Test in US (June 2026), Medicare coverage secured for TrueMRD Monitoring Test in MIBC (May 2026), OPTIMA trial results presented at ASCO 2026 demonstrating Prosigna test identifies high-risk breast cancer patients who can safely avoid chemotherapy
Awards & Recognition
Decipher Prostate is the only gene expression test with high evidence quality status in NCCN Clinical Practice Guidelines for prostate cancer
Key Partnerships
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSimilar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.